HIMS 📈 Hims Hers Health - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4330001060

HIMS: Prescription Medication, Skincare, Haircare, Sexual Wellness, Supplements

Hims & Hers Health, Inc. is a telehealth company that facilitates connections between consumers and licensed healthcare professionals across the United States, the United Kingdom, and other international markets. The platform provides access to a wide range of health and wellness products, including prescription and non-prescription items, which can be purchased directly through their website or mobile application. This approach enables customers to take a more proactive and convenient approach to managing their health and wellness.

The company's product portfolio is diverse, encompassing prescription medications that can be dispensed on a recurring basis, as well as ongoing care services from healthcare providers. Additionally, they offer a variety of over-the-counter products, including drugs, devices, cosmetics, and supplements, with a focus on general wellness, sexual health, skincare, and hair care. For instance, their wellness products include melatonin and biotin, while their skincare line features moisturizers, creams, sunscreen, and face wash. They also cater to sexual health and wellness with products like condoms, climax delay sprays, and lubricants, and their hair care range includes shampoos, conditioners, and scalp treatments.

Furthermore, Hims & Hers Health, Inc. provides medical consultation services, offering customers the opportunity to consult with healthcare professionals and receive post-consultation support. The company also partners with wholesale providers to offer its health and wellness products, expanding its reach and accessibility. As a San Francisco, California-based company, Hims & Hers Health, Inc. operates with a strong online presence, including its website at https://www.forhims.com, and is listed on the New York Stock Exchange (NYSE) under the ticker symbol HIMS, with the ISIN US4330001060, classified as a common stock in the Health Care Services sub-industry.

Additional Sources for HIMS Stock

HIMS Stock Overview

Market Cap in USD 6,827m
Sector Consumer Defensive
Industry Household & Personal Products
GiC Sub-Industry Health Care Services
IPO / Inception 2019-09-13

HIMS Stock Ratings

Growth 5y 50.2%
Fundamental 78.9%
Dividend -
Rel. Strength Industry 4062
Analysts 3.42/5
Fair Price Momentum 25.94 USD
Fair Price DCF 19.74 USD

HIMS Dividends

No Dividends Paid

HIMS Growth Ratios

Growth Correlation 3m 85.9%
Growth Correlation 12m 81.7%
Growth Correlation 5y 11.1%
CAGR 5y 21.92%
CAGR/Mean DD 5y 0.46
Sharpe Ratio 12m 1.62
Alpha 178.97
Beta 1.00
Volatility 107.27%
Current Volume 17296.3k
Average Volume 20d 16748.2k
What is the price of HIMS stocks?
As of December 22, 2024, the stock is trading at USD 26.20 with a total of 17,296,326 shares traded.
Over the past week, the price has changed by -12.72%, over one month by +20.24%, over three months by +60.74% and over the past year by +214.15%.
Is Hims Hers Health a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Hims Hers Health (NYSE:HIMS) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 78.94 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HIMS as of December 2024 is 25.94. This means that HIMS is currently overvalued and has a potential downside of -0.99%.
Is HIMS a buy, sell or hold?
Hims Hers Health has received a consensus analysts rating of 3.42. Therefor, it is recommend to hold HIMS.
  • Strong Buy: 2
  • Buy: 2
  • Hold: 7
  • Sell: 1
  • Strong Sell: 0
What are the forecast for HIMS stock price target?
According to ValueRays Forecast Model, HIMS Hims Hers Health will be worth about 28.8 in December 2025. The stock is currently trading at 26.20. This means that the stock has a potential upside of +10.08%.
Issuer Forecast Upside
Wallstreet Target Price 24.9 -5%
Analysts Target Price 12.3 -53.1%
ValueRay Target Price 28.8 10.1%